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ABSTRACT 
OPTIMIZING ALGINATE-CHITOSAN MICROCAPSULES USING CO-AXIAL 
AIR FLOW METHOD AS 3D STEM CELL MICROENVIRONMENT 
 
by 
Noel Alfonso 
Microencapsulation of cells is gaining popular interest in the field of biomedical 
engineering because it provides a more effective 3D scaffold that can mimic the cell 
microenvironment.  The benefits of using microcapsules are biocompatibility, 
biodegradability, nontoxicity, and formation under mild gelation conditions.  In this 
study, the ability of the alginate microcapsules to control the proliferation and 
differentiation of mouse OCT4-GFP embryonic stem cells is investigated.  Microcapsules 
are produced by extrusion of alginate into a calcium chloride gelation bath with the aid of 
a co-axial air flow.  It is shown that the size of the spheres is controlled based on needle 
gauge, air flow rate, and alginate concentration.  Coating the microcapsules with a 
chitosan membrane improves stability over time as their swelling behavior is examined.  
The surface of the microcapsules is further characterized using Fourier transform infrared 
(FTIR) spectroscopy and scanning electron microscopy (SEM).  Permeability of the 
microcapsules is studied through the release rate of encapsulated bovine serum albumin 
(BSA) and fluorescein isothiocynate-dextran (FITC-dextran) over time.  Finally, cell 
viability is tested by means of live-dead cell and resazurin assays of encapsulated cells.  
The proliferation and differentiation of encapsulated mouse OCT4-GFP embryonic stem 
cells are analyzed by flow cytometry.  It is shown that encapsulated cells are able to 
remain viable and that the microcapsule microenvironment is able to control the 
proliferation and differentiation of mouse OCT4-GFP embryonic stem cells.
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CHAPTER 1    
INTRODUCTION   
1.1 Microencapsulation Technology 
Cell therapy is becoming one of the popular methods to replace, repair, or enhance the 
function of damaged tissues or organs.  Prior to use, cells are maintained and cultured in 
vitro until it has reached its desired therapeutic state. The traditional methods of 
manipulating cells in a two dimensional (2D) culture system, such as Petri dishes, T-
flasks, or multi-wells surfaces, are becoming insufficient for the need of modern 
medicine.  These culturing conditions have limitations in not providing the necessary 
surface area needed for cell growth.  Consequently, the cells are unable to grow and 
expand in a large scale, which is required in cell therapeutic applications.  Another 
method of using cells for therapy involves the injection of cells at the site of injury or 
defect.  In regenerative medicine, the injection of cells at a defect site may be problematic 
as cells can not directly adhere to the tissue and could be washed away into the 
surrounding environment.  The problems of 2D culture systems and cell lost at 
implantation site are the reasons why injectable transporter materials, such as 
microcapsules, are gaining interest as cell carriers for tissue engineering [1].  The 
microencapsulation of cells is proven to be a valuable model in the research of gene 
therapy, artificial cells and organs, large-scale cell culture, and drug screening [4].  Cell 
microencapsulation involves the packaging of cells within a semi-permeable membrane.  
This membrane allows for the bi-directional diffusion of nutrients, oxygen, secreted 
therapeutic products, and metabolic wastes.  It also prevents the diffusion of high 
molecular weight substances, such as antibodies and immunocytes, from the cells [4].
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Microcapsules are also able to protect the encapsulated cells from the harsh external 
environment and immune response of the host and thus maintaining its useful biological 
activity.  The encapsulation of cells can also eliminate or reduce the use of 
immunosuppressant drugs if an immune response is triggered. 
In addition, microcapsules transition the two dimensional (2D) culture systems 
into three dimensional (3D).  This 3D culture system provides a special 
microenvironment that can affect the encapsulated cellular behaviors.  Microcapsules are 
able to provide a 3D matrix that better mimic the geometry, chemistry, and signaling 
environment of the natural extra cellular matrix (ECM) of cells in vivo.  Therefore, the 
use of microcapsules can better control the encapsulated cell properties.  
1.2 Cell Choice  
The choice of cell type for encapsulation depends on the intended application of the 
microcapsules.  Various cell types such as primary cells, stem cells, and bioengineered 
cells have been considered potentially therapeutic for the treatment of many diseases [6].  
A potential problem associated with the encapsulation of nonautologous cells is the high 
immunogenicity of the encapsulated cells which can trigger an unwanted immune 
response in the microenvironment surrounding the microcapsule.  This can lead to the 
suffocation and death of the encapsulated cells.  Additionally, differentiated cells are 
limited in availability.  One possible solution to overcome these problems is to choose a 
cell type that can reduce the host immune response and that are readily available.  Stem 
cells are becoming a popular cell choice for microencapsulation technology.  
Stem cells are a popular cell choice in regenerative medicine because they have 
the capability of reconstituting damaged tissues and maintaining normal tissues.  They 
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are also a good choice for tissues that do not have the ability to regenerate.  Briefly, stem 
cells are undifferentiated cells that have the ability to self-renew and differentiate.  The 
two major classes of stem cells are embryonic stem (ES) cells and adult stem cells.  Adult 
stem cells are known to be tissue specific.  This means that the microenvironment in 
which it came from determines the specific lineages the cell is able differentiate into.  On 
the other hand, embryonic stem cells have the potential of becoming more than one type 
of cell and termed to be pluripotent.  In either case, the differentiation of stem cells 
depends on the microenvironment in which it resides. 
1.3 Methods for Microcapsule Fabrication 
Various fabrication methods exist for the production of microcapsules.  Some of these 
techniques include spray-drying, vibrating nozzle, air-blast or twin-fluid atomization, 
emulsification or gelation, jet-cutting, extrusion under an electrostatic field, layer-by-
layer self assembly, and milling and grinding [1, 5].  The details of each method will not 
be discussed.  Although each process has its advantages, it also has some disadvantages.  
Each technique contains parameters that may be detrimental to the encapsulating 
material.  For example, the spray-drying technique is regarded as harsh because the 
drying gas requires a high temperature at which is harmful to sensitive biological 
materials.  The vibrating nozzle and jet-cutting methods are only limited to small-scale 
production.  In air-blast or twin-fluid atomization, the process is complicated and the 
extrusion solution is subjected to both tensile and shear stresses.  Emulsification or 
gelation requires many steps and rigid control of both the temperature and viscosity of 
emulsion.  In addition, the microcapsules must be washed thoroughly to remove the 
residual oil or organic solvents.  The application of an electrostatic field with a high 
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voltage is known to be a limitation for the extrusion under an electrostatic field method.  
The fabrication process for layer-by-layer self assembly is quite complicated.  Milling 
and grinding method requires large amounts of material, and this technique may result in 
the denaturation of proteins due to the high pressure at the pushing and grinding inlets.  
The mechanical stress may cause degradation of the proteins [5].  The choice of 
technique depends on the desired properties and application under study.  In particular, a 
gentle encapsulation technique is required if the viability of encapsulated cells is aimed.  
The fabrication method chosen for this study involves the extrusion of the microcapsule 
solution through a syringe needle with an air flow jet applied at the needle tip.  This 
method is effective, very simply, and relatively cheap. 
1.4 Microcapsule Critical Properties  
Some of the favorable properties of microcapsules include mild gelation conditions, 
biocompatibility, biodegradability, and nontoxicity [2].  Biocompatibility is defined as 
the ability of a biomaterial to perform with an appropriate host response in a specific 
application [6].  Furthermore, the microcapsule must not trigger an immune response if 
implantation into a host is intended.  For cell encapsulation, the microcapsule must have 
sufficient permeability to allow the nutrients and oxygen to enter and the metabolic 
cellular wastes products to leave the capsule in order to maintain cell viability and 
promote cell growth [1, 4].  In addition, the pores must be small enough such that 
unwanted large molecules will not enter or leave the capsule [1].  The microcapsules 
must also be able to maintain long term stability and integrity.  In cell encapsulation, the 
membrane isolates the cells from the external microenvironment of the host.  It must 
provide a strong barrier to ensure that there is no direct cell-cell contact between the 
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encapsulated cells and the host cells that can lead to an unwanted immune response.  The 
size of the microcapsules is also carefully considered as it found that it can influence the 
immune response on the microcapsules as well [6].  Sakai et al. concluded that the 
cellular reaction was much lower with the use of smaller microcapsules when compared 
to microcapsules of larger diameters [7].  This study tries to achieve these requirements 
necessary for the maintenance of cell function, growth, and viability of encapsulated 
cells.   
1.5 Biomaterials for Microencapsulation 
Biomaterials, such as polysaccharide-based hydrogels, are becoming increasingly 
important in the development of drug delivery systems and tissue engineering 
approaches[6].  Natural polymers are typically chosen as the primary components for 
microencapsulation due to their biocompatibility and biodegradability [8].  Most 
microcapsules that have been developed are alginate-based with a liquid core in the 
center.  Some of the advantages of using alginate include low toxicity and high 
biocompatibility with the host and with enclosed cells [3].  Alginates are natural 
polysaccharides derived from brown algae whose structure consists of two monomeric 
units, α-L-guluronic (G) and β-D-mannuronic (M) acid residues, that are linked by 1-4 
glycoside bonds [3, 8, 9].  These residues are arranged linearly in homopolymeric blocks 
(GG and MM) and in heteropolymeric blocks (GM) [9].  Figure 1.1 shows the structure 
of the two monomeric units of alginate and their arrangement.  Alginates are highly 
hydrophilic due to the presence of –OH and –COOH groups in its chains. 
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Figure 1.1  Alginate is composed of two monomeric units, (a) β-D-mannuronic acid and 
(b) α-L-guluronic acid.  These two units are arranged linearly as shown in (c). 
 
Source: Keita Kashima and Masanao Imai (2012). Advanced Membrane Material from Marine Biological 
Polymer and Sensitive Molecular-Size Recognition for Promising Separation Technology, Advancing 
Desalination, Prof. Robert Y. Ning (Ed.), ISBN: 978-953-51-0704-0, InTech, DOI: 10.5772/50734. 
Available from: http://www.intechopen.com/books/advancing-desalination/advanced-membrane-material-
from-marine-biological-polymer-and-sensitive-molecular-size-recognition-f 
 
Alginates are also known to form gels under relatively mild conditions at room 
temperature which allows the preservation of the biological activity of the encapsulated 
material [8].  The simplest and widely used method for the production of alginate 
microcapsules is based on the dropwise extrusion of alginate solution through a syringe 
with a needle into a gelation bath containing divalent cations.  The gelation of alginate 
polymers is formed through cross-linking between the carboxylate anions of guluronic 
acid and divalent cations [2, 8, 9].  This phenomenon is referred to as the egg-box model 
in which a divalent cation binds to two carboxyl groups on the adjacent alginate 
molecules [9].  The egg-box model is illustrated in Figure 1.2.  The result is a highly 
compacted gel network.  The selection of the divalent cations is carefully considered.  For 
example, monovalent cations and magnesium ions (Mg2+) do not induce gelation with 
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alginate.  On the other hand, other divalent cations such as lead (Pb2+), copper (Cu2+), 
cadmium (Cd2+), cobalt (Co2+), nickel (Ni2+), zinc (Zn2+), and manganese (Mn2+) is able 
to induce gelation.  However, they are not used because they are known to be toxic.  The 
commonly used divalent cation for the gelation of alginate is calcium (Ca2+) in calcium 
chloride (CaCl2) due to its biocompatibility and nontoxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2  The gelation of the alginate polymer is formed when a divalent cation binds 
to the alginate. 
 
Source: Keita Kashima and Masanao Imai (2012). Advanced Membrane Material from Marine Biological 
Polymer and Sensitive Molecular-Size Recognition for Promising Separation Technology, Advancing 
Desalination, Prof. Robert Y. Ning (Ed.), ISBN: 978-953-51-0704-0, InTech, DOI: 10.5772/50734. 
Available from: http://www.intechopen.com/books/advancing-desalination/advanced-membrane-material-
from-marine-biological-polymer-and-sensitive-molecular-size-recognition-f 
 
The long term structural integrity of the alginate gel network is questioned given 
the soft gelatinous nature of the material [10].  Since the gelation of alginate involves the 
ionic interaction between negatively charged alginate molecules and positively charged 
divalent cations, it may be possible for the divalent cations to diffuse out of the alginate 
matrix over a prolonged period. This would cause the bond between alginate and the 
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divalent cation to weaken resulting in a weaker gel that may dissolve or break [10].  
Coating of the microcapsules with a polycation, such as poly-L-lysine (PLL) or chitosan, 
can help stabilize the ionic gel network and reduce alginate permeability through 
electrostatic interactions with the negatively charged alginate acid groups [2, 8].  
Chitosan is gaining interest in replacing PLL in coating alginate microcapsules [11].  PLL 
is reported to induce foreign body reactions by activating macrophages and fibroblasts 
[11].  Chitosan is a naturally occurring polycationic polymer derived from the natural 
polymer chitin, which is found in the exoskeleton of crustaceans and insects [2].  
Chitosan is also a polysaccharide with structural characteristics similar to 
glycosaminoglycans [11].  The structure of chitosan is given in Figure 1.3. 
 
 
 
 
 
 
 
Figure 1.3  The structure of chitosan is comprised of D-glucosamine and N-acetyl-
glucosamine with unique polycation characteristics. 
 
Source: Thayza Christina Montenegro Stamford, Thatiana Montenegro Stamford-Arnaud, Horacinna Maria 
de Medeiros Cavalcante, Rui Oliveira Macedo and Galba Maria de Campos-Takaki (2013). 
Microbiological Chitosan: Potential Application as Anticariogenic Agent, Practical Applications in 
Biomedical Engineering, Dr. Adriano Andrade (Ed.), ISBN: 978-953-51-0924-2, InTech, DOI: 
10.5772/54453. Available from: http://www.intechopen.com/books/practical-applications-in-biomedical-
engineering/microbiological-chitosan-potential-application-as-anticariogenic-agent 
 
Chitosan is freely available and relatively cheap compared to PLL.  Furthermore, 
it is known to be nontoxic and bioabsorbable.  It has been investigated as a suitable 
polymer coating for oral delivery of proteins as well as the immobilization or delivery of 
living cells.  Chitosan is soluble in acid solutions when the pH is less than 6.0.  Thus, 
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acetic acid is often commonly used for preparing chitosan solutions for encapsulation 
processes.  Due to their excellent compatibility and nontoxicity, this study utilizes 
alginate as the microcapsule material and chitosan as the coating material. 
1.6 Objective  
The goal of this study is to optimize alginate-based microcapsules using a co-axial air 
flow method and apply these microcapsules as a 3D stem cell microenvironment.  
Specifically, the aims are (1) to fabricate and characterize alginate and alginate-chitosan 
microcapsules using a co-axial air flow method and (2) to evaluate cell encapsulation on 
cytocompatibility and stem cell proliferation and differentiation.  In this project, it is 
hypothesized that the alginate-based 3D microenvironment is able to control the 
proliferation and differentiation of embryonic stem cells. 
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CHAPTER 2    
MATERIALS AND METHODS 
2.1 Materials 
Alginic acid sodium salt from brown algae (250 cps at 25°C, 2% solution), low molecular 
weight chitosan (20 cps), coomassie brilliant blue R-250, and fluorescein isothiocynate-
dextran (FITC-dextran, molecular weight of 70kDa) are purchased from Sigma-Aldrich, 
USA.  Anhydrous calcium chloride, sodium chloride, sodium citrate, bovine serum 
albumin (BSA, bp 600-100), ethanol (95% denatured with MIKB), sodium cacodylate 
(Na-cacodylate) buffer, and glutaraldehyde (25% solution) are obtained from Fisher 
Scientific, USA.  Glacial acetic acid is provided by Ricca Chemical Company, USA. 
Fibroblast cells are cultured and maintained in fibroblast cell medium consisting 
of 1% penicillin-streptomycin, 10% horse serum, and 89% Dulbecco’s Modified Eagle 
Medium (DMEM) high glucose.  The fibroblast cells are passaged every one to two 
weeks.  The medium in the tissue culture dish is replaced every three days until time of 
passage.  Fibroblast cells are incubated at culture conditions of 37°C and 10% CO2. 
Mouse OCT4-GFP embryonic stem cells are cultured and maintained in 
undifferentiation medium consisting of ESGRO Murine Leukemic Inhibitory Factor (106 
units)(Millipore), 0.1mM 2-mercaptoethanol, 1.5M sodium bicarbonate, nonessential 
amino acids, 4mM L-glutamine, penicillin-streptomycin, knockout serum replacement, 
and knockout DMEM.  The mouse OCT4-GFP embryonic stem cells are passaged every 
two to three days with medium change occurring every day.  Mouse OCT4-GFP 
embryonic stem cells are incubated at culture conditions of 37°C and 10% CO2. 
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2.2 Preparation of Encapsulation Solutions 
Sodium alginate powder and calcium chloride pellets are weighed and dissolved in 
deionized water (dH2O) separately.  Low molecular weight chitosan powder is weighed 
and added to 0.15M CaCl2 solution making a chitosan solution of concentration 0.4%.  
Next, 0.5% glacial acetic acid is added.  This solution is placed on a stirring plate and 
mixed overnight at room temperature to ensure dissolving.  The solution is then filtered 
using a cell strainer to remove any debris and impurities from the solution.  The solution 
is kept at 4°C until it is time to be used.  
2.3 Preparation of Alginate Microcapsules 
Sodium alginate is dissolved in deionized water (dH2O).  The alginate microcapsules are 
generally formed by extruding 1mL of alginate solution through a syringe with a needle 
gauge into a gelling bath containing 20mL of 0.15M calcium chloride (CaCl2) dissolved 
in dH2O.  The distance from the tip of the syringe needle and the CaCl2 gelation bath is 
about 5cm.  An air flow by means of an air flowmeter is applied to the bottom end of the 
syringe as the alginate solution is extruded.  After extrusion, the alginate microcapsules 
are incubated in the 0.15M CaCl2 solution for 5-10 minutes at a stirring rate of about 60 
revolutions per minute (rpm).  This fabrication method is illustrated in Figure 2.1. 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1  The fabrication process of alginate microcapsules involves extruding the 
alginate solution into a calcium chloride gelation bath under gentle stirring.  An air flow 
is applied at the end of the syringe needle to aid in the microsphere formation. 
 
2.4 Optimization of Alginate Microcapsule Size 
The size of alginate microcapsules can be controlled based on adjusting certain variables.  
Initially in this study, the effect of needle gauge size and air flow rate are investigated.  
An alginate concentration of 1.5% is used and the method of fabrication is described in 
Section 2.3.  Alginate microcapsules are prepared using both 22 and 30 gauge needles.  
For each needle gauge, an air flow rate is applied at the needle as the alginate solution is 
extruded into the CaCl2 solution under gentle stirring.  Air flow rates of 0 SCFH, 7.5 
SCFH, 10 SCFH, 15 SCFH, and 20 SCFH are tested.  After extrusion and incubation in 
0.15M CaCl2 solution, the microcapsules are transferred into p60 non-treated tissue 
Co-axial Air 
Air Flowmeter 
Alginate Solution 
Syringe 
Needle Gauge 
Calcium 
Chloride 
Solution 
Magnetic Stir Bar 
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culture dishes and observed under an inverted light microscope at 2x magnification.  
Images are acquired via a Nikon digital camera connected to the microscope.  The 
microcapsules’ area, mean diameter, and shape factor are measured using SigmaScan Pro 
5 software. 
2.5 Swelling and Stability Test 
The effect of coating the alginate microcapsules with a chitosan membrane is studied.  
The swelling and stability of chitosan-coated microcapsules over time are compared with 
uncoated alginate microcapsules.  Microcapsules are produced as described in Section 
2.3.  Briefly, an alginate concentration of 1.5% is extruded through a syringe with a 30 
gauge needle into a 0.15M CaCl2 solution under gentle stirring.  An air flow rate of 15 
SCFH is applied at the end of the syringe.  Incubating the capsules in 0.4% chitosan in 
0.15M CaCl2 solution for 10 minutes following incubation in CaCl2 proceeding extrusion 
completion creates chitosan-coated microcapsules.  Both uncoated and chitosan-coated 
alginate microcapsules are washed with dH2O and incubated in phosphate buffer saline 
(PBS) at room temperature.  Microcapsules are observed under an inverted light 
microscope at 2x magnification until rupture is evident.  Images are taken with a Nikon 
digital camera connected to the microscope.  The microcapsules’ area, mean diameter, 
and shape factor are measured using SigmaScan Pro 5 software. 
2.6 Sphere Surface Characterization 
The surface comparison of uncoated and chitosan-coated alginate microcapsules is 
examined.  FTIR characterization is used to detect the presence and absence of chitosan 
on the coated and uncoated alginate microcapsules, respectively.  In addition, 
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microcapsules are stained with 5x coomassie brilliant blue R-250 and compared to 
discover success of coating with chitosan.  Scanning electron microscopy evaluates the 
difference in topography between the two microcapsule conditions. 
2.6.1 FITR 
Alginate microcapsules, both coated and chitosan-coated, are fabricated according to the 
aforementioned methods in Sections 2.3 and 2.5.  Following the incubation in CaCl2 for 
the uncoated alginate microcapsules and the incubation in 0.4% chitosan in 0.15M CaCl2 
for the chitosan-coated alginate microcapsules, the microcapsules are transferred into p35 
non-treated tissue culture dishes.  Excess solutions are removed and the microcapsules 
are washed with dH2O.  The dH2O is then aspirated and the microcapsules are placed into 
a vacuum desiccator to dry for at least 24 hours.  After 24 hours, the microcapsules are 
analyzed using Spectrum 100 FTIR Spectrometer (Perkin Elmer). 
2.6.2 Microcapsule Staining with Coomassie Protein Assay Reagent 
The method of manufacturing uncoated and chitosan-coated alginate microcapsules is 
similar to the technique described in Sections 2.3 and 2.5.  Following fabrication, the 
microcapsules are washed with dH2O and incubated in 5x coomassie brilliant blue R-250 
for about 10 minutes.  After 10 minutes, the coomassie brilliant blue R-250 is aspirated.  
The microcapsules are washed with dH2O and incubated in dH2O.  Microcapsules are 
observed under an inverted light microscope at 4x magnification.  Images are taken with 
a Nikon digital camera connected to the microscope. 
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2.6.3 Scanning Electron Microscopy 
Uncoated and chitosan-coated alginate microcapsules are produced following the same 
protocol performed in Sections 2.3 and 2.5.  After the incubation in CaCl2 for the 
uncoated alginate microcapsules and the incubation in 0.4% chitosan in 0.15M CaCl2 for 
the chitosan-coated alginate microcapsules, the microcapsules are incubated in 2.5% 
glutaraldehyde in 0.1M Na-cacodylate buffer (pH = 7.4) overnight at 4°C.  Next, the 
solution is aspirated and the microcapsules are washed with 0.1M Na-cacodylate buffer 
two times.  Microcapsules are dehydrated through the incubation in a series of ethanol for 
5-10 minutes each.  The series are 30%, 50%, 70%, and 95% ethanol.  After the 
aspiration of 95% ethanol, the microcapsules are placed in a chemical hood to air dry.  
Prior to scanning the samples, the microcapsules are mounted on metal stubs using 
double-sided adhesive tape, and coated with gold under a vacuum using a sputter coater 
unit.  The samples are then examined by scanning electron microscopy (SEM) (LEO 
1350 VP). 
2.7 Membrane Permeability 
The membrane permeability of both uncoated and chitosan-coated alginate microcapsules 
is studied through the encapsulation of BSA and FITC-dextran.  The release rate of each 
is monitored over time and quantified. 
2.7.1 BSA Encapsulation and Sustained Release 
To prepare the BSA encapsulated microcapsule, BSA is first dissolved in dH2O resulting 
in a BSA stock solution concentration of 400mg/mL.  The BSA stock solution is then 
mixed with 2.5% alginate solution resulting in a final BSA concentration of 20mg/mL.  
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The BSA-alginate solution is extruded dropwise into 20mL of 0.15M CaCl2 under gentle 
stirring through a syringe with a 30 gauge needle.  An air flow rate of 15 SCFH is applied 
at the needle gauge to aid in microcapsule formation.  The microcapsules are incubated in 
the CaCl2 at a stirring rate of 60 rpm for about 10 minutes.  The microcapsules are 
transferred and evenly distributed into three 3mL test tubes.  Any excess CaCl2 in the test 
tubes is aspirated.  The microcapsules are incubated in HEPES buffer solution and the 
test tube is placed into a water bath at 37°C for incubation.  At time points 10, 15, 75 
minutes, and days 1, 2, 3, 4, 5, 6, 7 after extrusion completion, a 1mL sample of 
incubation solution is taken.  The remaining solution is aspirated and replaced with 2mL 
of fresh HEPES buffer solution.  The Bradford colorimetric protein assay is used to 
detect the amount of protein secreted from uncoated and chitosan-coated alginate 
microcapsules containing BSA.  Ten BSA standards are prepared using a two-fold serial 
dilution beginning with BSA stock solution concentration of 500µg/mL.  The incubation 
solution samples and the ten BSA standards are placed into a 96-well plate and mixed 
with Coomassie brilliant blue R-250.  The samples and standards are analyzed by a 
spectrophotometer at a wavelength of 650nm using the software SoftMax Pro. 
The effect of coating the microcapsules with chitosan on the release rate of 
encapsulated BSA is also tested.  To create microcapsules with a chitosan coating, the 
microcapsules are transferred into 0.4% chitosan solution in 0.15M CaCl2 after 10 
minutes of incubation in CaCl2 under gentle stirring.  The microcapsules are incubated in 
the chitosan solution for 5 minutes.  After 5 minutes, the same protocol for the uncoated 
microcapsules is followed starting from the transfer of the microcapsules into a 3mL test 
tube. 
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2.7.2 FITC-dextran Encapsulation and Fluorescence Intensity 
FITC-dextran encapsulated microcapsules are prepared by mixing 50mg/mL stock 
solution of FITC-dextran with 2.5% alginate solution.  The resulting final concentration 
of encapsulated FITC-dextran is 1mg/mL.  The FITC-dextran-alginate solution is 
extruded into 20mL of 0.15 CaCl2 under gentle stirring through a syringe with a 30 gauge 
needle.  An air flow rate of 15 SCFH is applied at the needle gauge to aid in microcapsule 
fabrication.  Upon extrusion completion, the microcapsules are incubated in the CaCl2 
solution at a stirring rate of 60 rpm for about 5 minutes.  Next, the microcapsules are 
transferred into a p60 non-treated tissue culture dish.  The excess CaCl2 in the dish is 
aspirated, the microcapsules are washed with HEPES buffer solution one time, and fresh 
HEPES buffer is added as the incubation medium.  Chitosan-coated microcapsules are 
created by incubating the microcapsules in 0.4% chitosan in 0.15M CaCl2 for 5 minutes 
after incubation in CaCl2 following extrusion completion.  The microcapsules are 
observed under a fluorescence microscope for 2 days at 2x magnification. Images of the 
microcapsules are taken with a Nikon digital camera connected to the microscope.  The 
microcapsules’ average fluorescence intensity is measured using SigmaScan Pro 5 
software. 
2.8 Cell Studies 
The alginate microcapsule microenvironment is explored through the encapsulation of 
cells.  The viability of encapsulated fibroblast cells are examined through live-dead cell 
and resazurin assays.  The encapsulation of mouse OCT4-GFP embryonic stem cells is 
studied to determine the effect of the microcapsule environment on stem cell proliferation 
and differentiation. 
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2.8.1 Fibroblast Cell Encapsulation for Live-dead Cell Assay 
Encapsulated fibroblast cells in alginate microcapsules are produced by mixing about 1.5 
million fibroblast cells of passage 15 with 1mL of 2.5% alginate solution.  The cell-
alginate solution is extruded through a syringe with a 30 gauge needle into 20mL of 
0.15M CaCl2 at a stirring rate of 60 rpm.  An air flow rate of 15 SCFH is applied at the 
needle gauge.  After extrusion completion, the microcapsules are incubated in the CaCl2 
under gentle stirring for 5 minutes.  Cells encapsulated in chitosan-coated microcapsules 
are created by incubating the microcapsules in 0.4% chitosan in 0.15M CaCl2 for an 
additional 5 minutes following the incubation in 0.15M CaCl2 after extrusion completion.  
The microcapsules are then transferred into four wells of a 24-well tissue culture plate.  
The excess CaCl2 in the wells are aspirated and the microcapsules are washed with 
HEPES buffer solution one time.  The microcapsules are incubated in 400µL of staining 
solution for 5 minutes.  The staining solution consists of HEPES buffer solution, calcein-
AM, and ethidium homodimer-1.  After 5 minutes, the microcapsules are observed using 
a fluorescence microscope at 2x magnification for live-dead cell analysis.  Images are 
taken by means of a Nikon digital camera connected to the microscope. 
2.8.2 Fibroblast Cell Encapsulation for Resazurin Assay 
The method of encapsulation of fibroblast cells is similar to that described in Section 
2.8.1.  After the washing of the microcapsules with HEPES buffer solution, 450µL of 
fibroblast medium and 50µL of 10x resazurin solution are added to each well containing 
fibroblast encapsulated spheres.  The encapsulated fibroblast cells are incubated in this 
solution for at least 1 hour at 37°C and 10% CO2.  After 1 hour, a 100µL of the solution 
is sampled from each well and placed into a 96-well plate.  The remaining solution in the 
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wells is aspirated and 500µL of fresh fibroblast medium is added.  The 24-well plate 
containing the microcapsules is incubated at 37°C and 10% CO2.  The collected samples 
are analyzed using a spectrofluorometer (Gemini XPS Fluorescence Microplate Reader) 
that would measure the fluorescence.  The samples are measured at an excitation 
wavelength of 530nm and an emission wavelength of 590nm.  The incubation and 
sampling of the resazurin solution is repeated for 5 days. 
2.8.3 Mouse Embryonic Stem Cell Encapsulation 
About 2 million mouse OCT4-GFP embryonic stem cells of passage 41 are encapsulated 
in alginate microcapsules following the same fabrication method described in Section 
2.8.1 for the encapsulation of fibroblast cells.  The microcapsules are transferred into p60 
treated tissue culture dishes.  The excess CaCl2 in the dish is aspirated and 4mL of 
differentiation medium is added.  The differentiation medium consists of DMEM, 10% 
fetal bovine serum (FBS), 1% penicillin-streptomycin, and 4mM L-glutamine.  The cells 
in the alginate microcapsules are maintained in culture in differentiation medium at 
culture conditions of 37°C and 10% CO2 for 2 days with medium change occurring every 
day. 
After 2 days of culture, the differentiation medium is aspirated and the 
microcapsules are washed with PBS.  In order to release the cells, the microcapsules are 
incubated in 0.2% NaCl in 100mM sodium citrate solution at 37°C for 30 minutes.  The 
cells in solution are collected into a 15mL conical tube and PBS is added. The tube is 
then centrifuged at 800rpm for 5 minutes.  Following centrifuge, the supernatant is 
discarded.  Next, the cells are incubated in 1mL of 1.6% paraformaldehyde (PFA) for 20 
minutes at room temperature.  After 20 minutes, about 9mL of PBS is added.  The 
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mixture is centrifuged and the cells are resuspended in PBS.  As a control condition, 
about 1 million undifferentiated OCT4-GFP mouse embryonic stem cells of passage 42 
are fixed with 1.6% paraformaldehyde following the same procedure just described.  The 
cells are characterized using flow cytometry by means of fluorescence-activated cell 
sorting (FACS). 
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CHAPTER 3    
RESULTS 
3.1 Effect of Needle Gauge Size and Air Flow Rate on Alginate Microcapsule Size 
Alginate microcapsules are fabricated by the extrusion of an alginate solution having a 
concentration of 1.5% through a syringe into a 0.15M CaCl2 coagulation bath.  Needle 
gauges of size 22 and 30 and the application of various air flow rates at the needle end are 
used to aid in the microcapsule fabrication.  Following fabrication, the alginate 
microcapsules’ area, mean diameter, and shape factor are analyzed using SigmaScan Pro 
5.  Shape factor measures the morphology of the microcapsules, and ranges from 0 to 1.  
The microcapsule can be associated to be a sphere if their shape factor value is 1 or close 
to 1; otherwise to an ellipse.  The results are summarized in Figure 3.1 and Table 3.1. 
 
Figure 3.1  Alginate microcapsules are fabricated with both 22 and 30 gauge needles.  
For each needle gauge, different air flow rates are applied at the needle tip.  Both needle 
gauge size and air flow rate affect the size of alginate microcapsules.  Comparison of 
microcapsule area is shown in (A) and mean diameter in (B). Data are expressed as mean 
± standard deviation.  
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As shown in Figure 3.1, the size of the alginate microcapsules decreases as both 
the needle gauge size and air flow rate increases.  All the alginate microcapsules that are 
produced by both 22 and 30 gauge needles at the various air flow rates reveal no 
significant difference in morphology.  Most of the alginate microcapsules produced in all 
conditions have shape factor values within the 0.87-0.89 range as it is given in Table 3.1.  
Since these values are relatively close to 1, this indicates a round morphology for the 
microcapsules. 
Table 3.1  Shape Factor Analysis of Alginate Microcapsule of Various Needle Gauges 
and Air Flow Rates 
 
Air Flow Rate (SCFH) Needle Gauge 22 Needle Gauge 30 
0 0.872 ± 0.006 0.891 ± 0.001 
7.5 0.873 ± 0.013 0.893 ± 0.001 
10 0.881 ± 0.007 0.895 ± 0.002 
15 0.885 ± 0.001 0.897 ± 0.002 
20 0.883 ± 0.007 0.892 ± 0.003 
 
3.2 Effect of Chitosan Coating on Microcapsule Stability 
Adding an additional chitosan membrane on the alginate microcapsules is studied to 
observe the effect it has on microcapsule stability.  After the fabrication of the alginate 
microcapsules using 1.5% alginate by extrusion through a syringe with a 30 gauge needle 
and an air flow rate of 15 SCFH into a CaCl2 gelling bath, the microcapsules are 
incubated in 0.4% chitosan in 0.15M CaCl2 solution for 5 minutes.  Microcapsules are 
washed with dH2O and incubated in PBS at room temperature for a few days.  The 
microcapsules are observed under an inverted light microscope at 2x magnification each 
day until microcapsule rupture.  The swelling and stability of uncoated and chitosan-
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coated microcapsules are compared.  The microcapsules’ area, mean diameter, and shape 
factor are analyzed using SigmaScan Pro 5.  The results are represented in Figure 3.2 and 
Table 3.2. 
 
Figure 3.2  The swelling and stability of uncoated and chitosan-coated alginate 
microcapsules are investigated.  Microcapsules are incubated in PBS and observed under 
an inverted light microscope for two weeks.  Comparison of microcapsule area is shown 
in (A) and mean diameter in (B).  Data are expressed as mean ± standard deviation. 
 
Referring to Figure 3.2, both uncoated and chitosan-coated microcapsules 
produced from 1.5% alginate solution extruded through a 30 gauge needle with an air 
flow rate of 15 SCFH have an average mean diameter of about 0.75-0.80mm following 
fabrication.  After the first day, all of the microcapsules show signs of swelling due to 
water absorption.  Uncoated microcapsules show more signs of swelling as their average 
mean diameter increased to about 0.89mm which is a 14% increase.  The average mean 
diameter of chitosan-coated microcapsules increased 4% from their original size to 
0.78mm, which is still relatively close to the average mean diameter on the first day 
following fabrication.  The microcapsules continue to swell as it is evident by the 
increase of mean diameter and area each day.  After day 14, the mean diameter and area 
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of uncoated alginate microcapsules decrease dramatically as they indicate rupture of the 
microcapsules.  This means that by day 14, the uncoated alginate microcapsules have 
reached their maximum size.  By this time the average mean diameter of the uncoated 
alginate microcapsules is about 1.78mm, which is approximately a 1mm increase.  The 
uncoated alginate microcapsules are swelled to more than twice their original size.  On 
the other hand, the chitosan-coated alginate microcapsules continue to remain stable and 
swell.  Comparing to the maximum size of uncoated microcapsules before rupture, the 
average mean diameter of chitosan-coated microcapsules is measured to be about 
0.90mm.  Their time of rupture is not known for monitoring ended on day 16 when the 
rupture of the uncoated alginate microcapsules was observed.  The average mean 
diameter of the chitosan-coated microcapsules on day 16 is about 0.91mm.  Figure 3.3 
shows the images of the uncoated and chitosan-coated alginate microcapsules following 
fabrication and day 16. 
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Figure 3.3  Microscopic images of uncoated and chitosan-coated alginate microcapsules 
taken on day 0 following fabrication and day 16.  Images are taken with a Nikon digital 
camera connected to an inverted light microscope.  For the images of uncoated 
microcapsules, microcapsules are viewed at 2x magnification on day 0 and at 4x 
magnification on day 16.  For the images of chitosan-coated microcapsules, 
microcapsules are viewed at 2x magnification on days 0 and 16.  On day 0, 
microcapsules are stable and have not yet swelled.  By day 16, uncoated alginate 
microcapsules have ruptured while chitosan-coated microcapsules remain stable. 
 
 
The results illustrated in Figure 3.2 prove that coating the alginate microcapsules 
with a chitosan membrane offers a more stable sphere with a reduced swelling rate 
compared to uncoated alginate microcapsules. 
Despite the increase in area and mean diameter over time, both uncoated and 
chitosan-coated alginate microcapsules are able to maintain their circular shape as given 
by their shape factor values for the 16 days of observation.  All the microcapsules of both 
conditions have shape factor values of about 0.89 as it can be seen in Table 3.2. 
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Table 3.2  Shape Factor of Uncoated and Chitosan-coated Alginate Microcapsules 
 
Day Uncoated Chitosan-coated 
0 0.897 ± 0.003 0.896 ± 0.002 
1 0.896 ± 0.001 0.894 ± 0.005 
2 0.894 ± 0.007 0.896 ± 0.003 
5 0.898 ± 0.002 0.901 ± 0.002 
7 0.893 ± 0.007 0.889 ± 0.007 
9 0.890 ± 0.004 0.887 ± 0.014 
12 0.897 ± 0.002 0.892 ± 0.006 
14 0.892 ± 0.007 0.893 ± 0.006 
16 0.884 ± 0.004 0.894 ± 0.003 
 
3.3 Characterization of Microcapsule Surface 
Uncoated and coated alginate microcapsules vary from each other based on the chemical 
composition on their outer surface.  The surface distinction between the microcapsules is 
characterized using FTIR, coomassie brilliant blue R-250 staining, and SEM.  
After the fabrication and drying of the uncoated and chitosan-coated alginate 
microcapsules, FTIR is used to determine the particular functional groups present on the 
surface.  The microcapsule FITR spectra are compared with the FTIR readings of alginate 
and chitosan compounds.  All samples are read at scan number 100 and a resolution at 
8cm-1.  Figures 3.4 and 3.5 provide the FTIR spectra for uncoated and chitosan-coated 
alginate microcapsules as well as alginate and chitosan, respectively. 
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Figure 3.4  The FTIR spectra of alginate and chitosan powders are compared with the 
FTIR spectra of uncoated and chitosan-coated alginate microcapsules. 
 
 
Figure 3.5  The surface of both uncoated and chitosan-coated alginate microcapsules are 
characterized using FTIR. 
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It is important to recall the chemical structures of both alginate and chitosan 
presented in Figures 1.1 and 1.3, respectively, in order to associate the peaks of the FITR 
spectra with the appropriate functional group.  The FTIR spectrum of chitosan powder in 
Figure 3.4 shows a weak band of –OH stretching at 2876cm-1.  An absorption band of the 
carbonyl (C=O) stretching of the secondary amide (amide I band) is observed at 1652cm-
1.  The bending vibrations of the N-H (N-acetylated residues, amide II band) can be found 
at wavenumber at 1591cm-1.   The peaks at 1423cm-1 and 1378cm-1 correspond to the N-
H stretching of the amide and ether bonds and N-H stretching (amide III band), 
respectively.   The peaks at 1065cm-1 and 1029cm-1 are the secondary (characteristic peak 
of –CH-OH in cyclic alcohols, C-O stretch) and primary (characteristic peak of –CH2-OH 
in primary alcohols, C-O stretch) hydroxyl groups, respectively.  The strong absorption 
peaks on the FTIR spectrum of alginate appear at 1598cm-1 and 1409cm-1 for the 
asymmetric and symmetric stretching vibrations of carboxyl anions.  The bridge oxygen 
(C-O-C, cyclic ether) stretching bands are observed at 1029cm-1 [12].   
The plot in Figure 3.5 shows the ability of FTIR to detect the presence of chitosan 
on the alginate microcapsules.  In both FTIR spectra of uncoated and chitosan-coated 
alginate microcapsules, the characteristic absorption band peaks of alginate and chitosan 
at 1607cm-1, 1425cm-1, 1079cm-1, and 1038cm-1 are observed.  The absorption band at 
1590cm-1 of chitosan in Figure 3.4 shifts to 1605cm-1 after the reaction with alginate as 
seen in Figure 3.5.  Although similar peaks are relatively obvious on both curves, there 
are peaks that are not so noticeable that differentiates the two curves.  The important peak 
that is present on the chitosan-coated alginate microcapsule curve and not present on the 
uncoated alginate microcapsule curve occurs at wavenumber 1564cm-1.  This peaks 
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indicates the presence of a –NH2 functional group in the bending position.  The detection 
of the –NH2 functional group proves that chitosan can be detected on the surface of the 
coated alginate microcapsules. 
Next, staining the microcapsules with 5x coomassie brilliant blue R-250 
following fabrication is used to detect the presence of chitosan on the surface of the 
spheres.  Microcapsules are observed under an inverted light microscope at 4x 
magnification and images are taken with a Nikon digital camera connected to a 
microscope.  The microscopic images of the stained alginate microcapsules are illustrated 
in Figure 3.6. 
 
Figure 3.6  Uncoated (A) and chitosan-coated (B) alginate microcapsules are stained 
with 5x coomassie brilliant blue R-250 and compared.  Staining is successful in all the 
microcapsules.  However, the coomassie brilliant blue R-250 is more evident in the 
chitosan-coated alginate microcapsules compared to the uncoated alginate microcapsules. 
 
 
Finally, scanning electron microscopy is used to examine the difference in surface 
topography between uncoated and chitosan-coated alginate microcapsules.  The SEM 
images in Figure 3.7 show the distinction between the two conditions.  The SEM 
micrographs of dried alginate microcapsules in Figure 3.7 (A) and (C) show the surface 
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to be relatively smooth with a few wrinkles.  The incorporation of chitosan on the 
microcapsule surface does not cause any significant change in the overall shape and size.  
However, the surface of chitosan-coated alginate microcapsules doesn’t seem as smooth 
as the uncoated alginate microcapsules.  They tend to have more wrinkles on the surface 
compared to the uncoated microcapsules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7  Scanning electron microscope (SEM) images (A) and (B) show an overview 
at 200x magnification for uncoated and chitosan-coated microcapsules, respectively.  
Images (C) and (D) show the surface structure at 1Kx magnification of uncoated and 
chitosan-coated alginate microcapsules, respectively. 
 
3.4 Permeability of Microcapsules 
The permeability of the uncoated and chitosan-coated alginate microcapsules is studied 
through the encapsulation of BSA and FITC-dextran.  Both BSA and FITC-dextran are 
encapsulated in the microcapsules through mixing with the alginate solution prior to 
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extrusion into the CaCl2 coagulation bath.  The microcapsules are incubated in HEPES 
buffer solution over time.  The release rate of each are monitored and quantified. 
The permeability of BSA is analyzed through the quantification of the amount of 
BSA released each day.  The measurement of the accumulated amount of BSA is 
presented in Figure 3.8.  The amount of BSA released from the microcapsules during the 
fabrication and washing steps is shown in Figure 3.8 (A).  From Figure 3.8 (A), a 
significant amount of BSA is released during the initial time period, particularly during 
the washing steps.  An estimated amount of 40% of the encapsulated BSA is released 
from both microcapsule conditions.  The amount of BSA released from the microcapsules 
each day proceeding fabrication is given in Figure 3.8 (B).  As it is expected, BSA 
diffuses out of the microcapsules each day in a sustained release profile.  However, more 
BSA is released from uncoated alginate microcapsules compared to the chitosan-coated 
alginate microcapsules. 
Figure 3.8  The accumulated amount of BSA released from both uncoated and chitosan-
coated alginate microcapsules is quantified by the Bradford colorimetric protein assay 
using a spectrophotometer. (A) illustrates the accumulated amount of BSA released from 
the microcapsules during the fabrication and washing steps.  (B) provides the 
accumulated release of BSA curves for uncoated and chitosan-coated microcapsules.  
Data are expressed as mean ± standard deviation. 
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The encapsulation of FITC-dextran is next investigated.  The permeability of 
FITC-dextran is evaluated by measuring the fluorescence intensity in the microcapsules 
each day using SigmaScan Pro 5.  Figure 3.9 shows the microscopic images of 
encapsulated FITC-dextran in uncoated and chitosan-coated alginate microcapsules on 
each day for 2 days.  
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Figure 3.9  The microphotographs of encapsulated FITC-dextran in uncoated and 
chitosan-coated alginate microcapsules are shown above.  Images are captured with an 
inverted light microscope at 2x magnification. 
 
 From the microscopic images in Figure 3.9, it is evident that FITC-dextran is able 
to diffuse out of the microcapsules over time.  After the first day of incubation in HEPES 
buffer solution, a significant amount of FTIC-dextran is released from the uncoated 
alginate microcapsules compared to the chitosan-coated alginate microcapsules.  By day 
2, the fluorescence of the uncoated alginate microcapsules is barely noticeable when 
viewed under the inverted light microscope.  On the other hand, the fluorescence of the 
33 
 
 
 
chitosan-coated alginate microcapsules is still detectable.  The microcapsules are also 
observed on day 3, but the data are not presented here.  On day 3, the fluorescence of the 
uncoated alginate microcapsules is not observed at all.  The chitosan-coated alginate 
microcapsules are able to display some fluorescence, but it is barely visible.  Using the 
microscopic images in Figure 3.9, the average fluorescence intensity of the microcapsules 
are measured using SigmaScan Pro 5.0.software.  The results are presented in Figure 
3.10. 
 
 
 
 
 
 
 
 
 
Figure 3.10  The average fluorescence intensity of encapsulated FITC-dextran tends to 
decrease over time as they are released from the microcapsules.  Data are expressed as 
mean ± standard deviation. 
 
The plot of average intensity in the microcapsules over time in Figure 3.10 
correlates with the visual observation of the fluorescence intensity in the microcapsules in 
Figure 3.9.  A significant amount of FITC-dextran is released after the first day of 
incubation in HEPES buffer solution from the uncoated alginate microcapsules; thus 
reducing its average fluorescence intensity from 100% down to 27%.  By day 2, the 
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average fluorescence intensity is decreased to about 18%.  FITC-dextran is slowly 
diffused out of the chitosan-coated alginate microcapsules as their fluorescence remain 
strongly evident after the first day.  The average fluorescence intensity of the chitosan-
coated alginate microcapsules decreases from 100% to 90%.  By day 2, the average 
fluorescence intensity is measured to be about 62%. 
The  encapsulation of BSA and FITC-dextran studies reveal that the permeability 
of chitosan-coated alginate microcapsules is reduced compared to uncoated alginate 
microcapsules.  This is evident through the slower release of both BSA and FITC-dextran 
from the chitosan-coated microcapsules.  These studies also prove that the permeability 
of the microcapsules can be controlled by coating the alginate microcapsules with 
chitosan. 
3.5 Microencapsulation of Cells 
The effect of the alginate microcapsule microenvironment on cell viability, proliferation, 
and differentiation is studied.  The encapsulation of fibroblast cells is used to determine if 
cells are able to remain viable throughout the fabrication process of the microcapsules 
and during incubation. Cell viability is tested by means of live-dead cell and resazurin 
assays.  The results from the live-dead cell assay are presented in Figure 3.11.  The 
microcapsules are observed using a fluorescence microscope at 2x magnification.  
Microscopic images of phase, live, dead, and live-dead states are taken with a Nikon 
digital camera connected to the microscope.  The generation of microcapsules by the co-
axial air flow method did not significantly affect the viability of encapsulated fibroblast 
cells.  As it can be seen in Figure 3.11, approximately 70% of the cells remained viable in 
both uncoated and chitosan-coated alginate microcapsules following the fabrication 
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process.  The results show that fibroblasts cells can be encapsulated in alginate 
microcapsules while maintaining their viability. 
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Figure 3.11  Live-dead cell assay for fibroblast cells encapsulated in alginate 
microcapsules. 
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The resazurin assay is used to determine whether cells are able to remain alive 
during incubation for a couple of days.  The resazurin assay quantifies the number of 
viable cells within the uncoated and chitosan-coated alginate microcapsules over time.  
Figure 3.12 illustrates the result from the resazurin assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12  The viability of fibroblast cells is examined through a resazurin assay.  In 
both uncoated and chitosan-coated alginate microcapsules, the number of live cells 
decreased over time.  Data are expressed as mean ± standard deviation. 
 
Based on the plot in Figure 3.12, the number of viable cells is similar in uncoated 
and chitosan-coated alginate microcapsules.  In both cases, the number of viable 
fibroblast cells decreases over time during incubation.  However, there appears to be 
more viable fibroblast cells in the uncoated alginate microcapsules compared to the 
chitosan-coated alginate microcapsules.  After the first day, about 23% and 16% of the 
cells remain viable in uncoated and chitosan-coated alginate microcapsules, respectively.  
By day 2, there is an increase in the number of viable cells; but the number continues to 
decline for the following days. 
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The effect of the microcapsule microenvironment on the proliferation and 
differentiation of stem cells is also investigated.  Images of encapsulated mouse OCT4-
GFP embryonic stem cells in uncoated and chitosan coated alginate microcapsules as 
well as the GFP expression of the encapsulated cells are provided in Figure 3.13.  Images 
are taken at 4x magnification with a Nikon digital camera connected to an inverted light 
microscope. 
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Figure 3.13  Mouse OCT4-GFP embryonic stem cells are encapsulated in uncoated and 
chitosan-coated alginate microcapsules following fabrication.  GFP expressions of 
encapsulated mouse OCT4-GFP embryonic stem cells are revealed using fluorescence 
microscopy.  Microscopic images are taken at 4x magnification following microcapsule 
fabrication. 
 
Following the encapsulation of mouse OCT4-GFP embryonic stem cells, the 
microcapsules are incubated in differentiation medium for 2 days at 37°C and 10% CO2 
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with medium change occurring every day.  After 2 days, the proliferation and 
differentiation of the stem cells are analyzed using flow cytometry by means of 
fluorescence-activated cell sorting (FACS).  The proliferation and differentiation of the 
encapsulated mouse OCT4-GFP embryonic stem cells is compared to the 
nonencapsulated state.  Figure 3.14 provides the results from flow cytometry analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14  Flow cytometry analysis of encapsulated mouse OCT4-GFP embryonic 
stem cells after 2 days of culture.  The results reveal that the alginate microcapsule 
microenvironment can influence stem cell proliferation and differentiation. 
 
Figure 3.14 shows that about 85% of the mouse embryonic stem cells expressed 
the OCT4-GFP gene when encapsulated in uncoated alginate microcapsules.  On the 
other hand, about 92% of the stem cells expressed the OCT4-GFP gene when 
encapsulated in chitosan-coated alginate microcapsules.  In summary, less OCT4-GFP 
expression means that more of the stem cells had differentiated.  More expression of the 
OCT4-GFP gene reveals either slower differentiation or undifferentiation of mouse 
OCT4-GFP embryonic stem cells. 
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CHAPTER 4    
DISCUSSION 
 
The goal of this study is to optimize the physical properties of alginate-based 
microcapsules using a co-axial air flow method and examine how the 3D culture system 
of alginate microcapsules affects the proliferation and differentiation of mouse OCT4-
GFP embryonic stem cells.  Prior to the encapsulation of mouse OCT4-GFP embryonic 
stem cells, the necessary parameters for the alginate microcapsules are first determined.  
In biomedical applications, the microcapsules should have appropriate characteristics 
such as a round morphology, large pore sizes, and smooth surfaces in order to properly 
facilitate the bi-directional diffusion of the encapsulated material and surrounding 
environment.  In addition, the microcapsule properties must be able to support cell 
physiological activities, such as metabolism, proliferation, migration, etc. for cell survival 
and function [3, 13, 14].  The selected materials for encapsulation fabrication should be 
compatible with the encapsulated material such that they do not disrupt its biological 
activity [2].  The microcapsules must also be mechanically stable and have long term 
integrity.  These properties can be achieved by optimizing the size of the microcapsules 
to small dimensions.  Small microcapsules are found to be mechanically stable due to the 
small diameter and large surface area to volume ratio [3, 6, 15].  It is important that 
microcapsules maintain the structural integrity and mechanical strength during its 
application [3]. 
In this study, microcapsules are produced by the extrusion of an alginate solution 
through a needle gauge with an application of an air flow.  Microcapsule size can be
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 controlled by process parameters and liquid properties of the extrusion solution.  The 
optimization of microcapsule size is investigated by varying the needle gauge size, air 
flow rate, and alginate concentration.  The experiment of the effect of alginate 
concentration on microcapsule size is presented in Appendix.  It is found that increasing 
the alginate concentration results in larger microcapsules.  This is due to the increase in 
the viscosity of the alginate solution.  Alginate solutions greater than 5% are difficult to 
prepare; and therefore is not generally used [9].  It is for this reason that the alginate 
concentration must remain below this value.  The viscosity of the alginate solution not 
only affects microcapsule size, but also the shape of the spheres produced.  The spheres 
become more spherical as the concentration of the alginate solution is increased.  It is 
also known that the distance between the tip of the syringe needle and the gelation bath 
affects mainly the shape of the drops and thus the microcapsules.  Munarin et al. found 
that the best results were obtained at a distance of 5cm [1]. 
Increasing the alginate solution concentration not only results in large 
microcapsules, but also in a decrease in microcapsule pore size; thus limiting diffusion 
[3].  Microcapsules larger than 1mm suffer from diffusion limitations that can result in 
reduced cell growth and cell death for encapsulated cells [16].  As mentioned previously, 
a microcapsule of small size with large pores is desired to efficiently facilitate diffusion.  
A higher membrane permeability offers a higher rate of nutrient exchange [16].  
Therefore, an alginate concentration of low viscosity must be selected in order to produce 
small microcapsules with large pores.  Based on the effect of alginate concentration on 
microcapsule size study, an alginate solution of 1.5% concentration is selected as the 
starting microcapsule material. 
41 
 
 
 
Not only must the microcapsules be small and have large pores, but they must 
also have a round morphology.  Microcapsules are characterized for round morphologies 
by measuring their shape factor.  The microcapsule can be associated to be a sphere if 
their shape factor is 1 or near 1; otherwise it is characterized to be an ellipse.  The effect 
of needle gauge size and air flow rate on microcapsule size is studied.  As it can be seen 
from Figure 3.1, microcapsule size decreases as needle gauge size and air flow rate both 
increase.  Although the increase in air flow can result in smaller microcapsules, the 
number of microcapsules with round morphologies tends to decrease even though their 
shape factors are estimated to be 0.89.  For example, microcapsules are produced by a 30 
gauge needle with an alginate concentration of 1.5% and with air flow rates of 0, 7.5, 10, 
15, and 20 SCFH.  Air flow rates from 0 – 15 SCFH are able to produce round 
microcapsules, but anything higher than 15 SCFH, such as the 20 SCFH air flow rate, the 
round morphology of some of the capsules becomes distorted as shown in Figure 4.1.  As 
a result, 15 SCFH is chosen as the air flow rate for the fabrication of alginate 
microcapsules in this study. 
 
 
 
 
 
 
Figure 4.1  Alginate microcapsules fabricated from 30 gauge needle, 1.5% alginate 
concentration, and 20 SCFH air flow rate result in irregular shaped spheres.  Non-
spherical shaped microcapsules are indicated by red arrows.  Microcapsules are viewed 
under an inverted light microscope at 2x magnification. 
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It is important that the microcapsules maintain their structure and stability.  Early 
rupture of the microcapsules would lead to the release of the entrapped drugs or cells 
before its intended application.  The stability of the alginate microcapsules is further 
examined by adding an additional membrane coating, chitosan, on the surface of the 
sphere.  Chitosan binds to the surface of the microcapsule thus creating a thin membrane 
with small pores.  Chitosan is known to increase the stability of the alginate 
microcapsules and is able to minimize the loss of encapsulated material through ionic 
cross-linking with the carboxylic residues of sodium alginate.  The electrostatic 
interaction between carboxylate groups of alginate and ammonium groups of chitosan 
leads to the formation of the chitosan-alginate polyelectrolyte complex [17].  Choosing 
the right chitosan concentration to coat the microcapsules is very important.  If the 
chitosan concentration is too low, the stability of the microcapsules is not sufficient.  
However, if the chitosan concentration is too high, the permeability would be reduced 
due to the increase in chitosan-alginate complexes; therefore forming a stronger closer 
network [17].  A study conducted by Yu et al. demonstrated that 0.4% chitosan solution 
had the best reinforcement efficiency resulting in a slower release of the encapsulated 
substance [17].  Hence 0.4% chitosan solution is used in this work to coat the alginate 
microcapsules. 
In this study, we examined the swelling behavior and stability of the alginate 
microcapsules.  Both uncoated and chitosan-coated alginate microcapsules are incubated 
in PBS and monitored for two weeks.  The results from the study reveal that uncoated 
alginate microcapsules swelled at a faster rate compared to the chitosan-coated alginate 
microcapsules.  The explanation for the outcome could be that the alginate microcapsule 
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surface is directly exposed to the aqueous environment that it is placed in, which is in this 
case PBS.  Alginate is highly hydrophilic due to the presence of –OH and –COOH groups 
in its chains.  At neutral pH, water enters the chains of alginate and forms hydrogen 
bridges with the –OH and –COO- groups.  Consequently, the alginate egg-box model is 
slowly weakened and the alginate microcapsules swell.  The swelling and rupture of 
alginate microcapsules is also due to the precipitation of calcium ions that would reverse 
alginate cross-linking when the spheres are incubated in PBS [3].  As there is a gradual 
decrease in the number of calcium alginate bonds, there is a decrease in gel strength and 
increase in permeability [1, 18, 19].  Adding an additional chitosan membrane on the 
alginate microcapsules can minimize the matrix swelling and increase stability.  The 
chitosan-alginate polyelectrolyte complexes are difficult to break.  The importance to 
monitor swelling behavior over time is to give an indication of the mechanical properties 
and durability of the microcapsules.  The aqueous environment is one of the factors 
involved in the in vivo release kinetics of cells and drugs [1]. 
Next, the surface of the alginate microcapsules is characterized using FTIR, 
coomassie brilliant blue R-250 staining, and SEM.  Each of these studies examine the 
absence or presence of chitosan on the surface of the alginate microcapsules.  Alginate 
and chitosan powders are also scanned by FTIR for comparison with the FTIR spectra of 
uncoated and chitosan-coated alginate microcapsules.  Recall that the gelation of alginate 
occurs when the carboxylate anions of guluronic acid crosslinks with the Ca2+ divalent 
cation.  In addition, coating of the alginate microcapsules with chitosan occurs when the 
ammonium groups of chitosan crosslinks with the carboxylate groups of alginate thus 
forming the chitosan-alginate polyelectrolyte complex.  FTIR analysis is able to detect 
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the structural modifications occurring in the polysaccharides during the formation of 
ionic crosslinks and polyelectrolyte complexes.  The formation of crosslinks or 
polyelectrolyte complexes modifies the original structure of polysaccharides [1].  
Therefore, the FTIR spectra of alginate and chitosan powders shift slightly in the FTIR 
spectra of uncoated and chitosan-coated alginate microcapsules though still remaining 
similar curves to their individual counterparts.  The most important peak that indicates 
the presence of chitosan on the alginate microcapsule surface occurs at wavenumber 
1564cm-1, which is not present on the uncoated alginate microcapsule spectrum. 
The presence of chitosan on the alginate microcapsule surface is also detected 
through the staining of the microcapsules with coomassie dye brilliant blue R-250.  The 
results presented in Figure 3.6 show that the chitosan-coated alginate microcapsules are 
stained well when compared to the staining of the uncoated microcapsules.  The 
negatively charged coomassie brilliant blue R-250 would strongly bind to the positively 
charged chitosan polymer.  The uncoated microcapsules are not stained well with the 
coomassie dye because the alginate polymer is also negatively charged.  The binding of 
two negatively charged molecules is undesired.  The structure of coomassie brilliant blue 
R-250 is illustrated in Figure 4.2. 
 
 
 
 
Figure 4.2  The structure of coomassie brilliant blue R-250 consists of a negatively 
charged sulfate group. 
 
Source: Syrovy, L. and Hodny, Z. (1991). Staining and quantification of proteins separated by 
polyacrylamide gel electrophoresis. J. Chromatog. 569, 175-196. 
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The surface topography of both uncoated and chitosan-coated alginate 
microcapsules are observed using SEM.  The scanning electron micrographs of uncoated 
alginate microcapsules reveal a smooth surface.  On the other hand, a few wrinkles, 
though not many, can be seen on chitosan-coated microcapsules.  This could be due to 
the dehydration of the chitosan membrane surrounding the microcapsule [5].  In both 
conditions, the microcapsules are able to maintain their round morphology.  Remember 
that round microcapsules with smooth surface are needed to aid in the diffusion of 
molecules into and out of the microcapsules. 
Membrane permeability is an important characteristic of microcapsules for the 
encapsulation of cells.  The permeability of the microcapsules is needed for the diffusion 
of oxygen and nutrients into the spheres in order to reach the encapsulated cells for 
growth and survival.  In addition, diffusion of metabolic waste products and therapeutic 
molecules are needed to exit the microcapsules.  Low molecular weight substances could 
be diffused out quickly and easily from the microcapsules leading to fast release and low 
encapsulation efficiency [17].  The permeability of the membrane is dependent on several 
properties such as charge distribution, porosity, hydrophilicity, and the properties and 
size of the substance being transferred across the membrane.  These characteristics vary 
depending on the interaction of chitosan with alginate [20]. 
In this study, the permeability of the microcapsules is tested through the 
encapsulation and release of BSA and FITC-dextran.    BSA is chosen for encapsulation 
because it is known to be an appropriate model protein in determining the permeability of 
microcapsules that are designed for biological systems.  For the fabrication of the 
microcapsules, the alginate concentration is increased from 1.5% to 2.5% because it is 
46 
 
 
 
found that the microcapsules produced with 1.5% alginate following the mixing of the 
alginate solution with BSA and FITC-dextran resulted in tear drop shaped spheres.  This 
is due to the dilution of the alginate solution once it is mixed with the encapsulated 
material.  From the results of the BSA encapsulation study, a possible explanation for the 
significant amount of BSA released following fabrication and washing is the shape of the 
microcapsules produced.  The microcapsules are not observed under an inverted light 
microscope for microsphere morphology.  Microsphere morphology can greatly influence 
drug release behavior.  Thus it is important to maintain the round morphology of the 
microcapsules.  Another reason could be traced to the continuing formation of the ionic 
crosslinks and polyelectrolyte complexes of the microcapsules following fabrication.  
This would lead to the leakage of some of the encapsulated BSA out of the 
microcapsules. 
Diffusion of the FITC-dextran molecules through the microcapsules is tracked by 
fluorescence microscopy.  The results are presented in Figures 3.9 and 3.10.  Based on 
the release studies of BSA and FITC-dextran, the microcapsules contain pore sizes large 
enough for nutrients in the cell culture medium to enter and reach to the encapsulated 
cells.  Most differentiation agents, such as growth factors, typically have a lower 
molecular weight compared to the 70kDa FITC-dextran. 
The microcapsule parameters reflecting cell viability and proliferation have to be 
defined for better application.  The viability, proliferation, and metabolic activity of cells 
within the microcapsule can be influenced by factors such as the fabrication process, 
chemical and physical properties of the matrix material, microenvironments, etc. [3].  For 
example, recall that alginate solutions of high concentration result in larger size 
47 
 
 
 
microcapsules.  The increase of microcapsule diameter would result in the reduction of 
cell viability.  Alginate solutions with high concentration have higher surface tension, 
thus reducing the cell viability in the generated microcapsules [3].  In addition, nutrients 
and oxygen would not be able to reach the cells towards the center of the microcapsule as 
it would reach the cells on the outer ends in the microcapsule first.  This would also result 
in a decrease in cell viability.  The factors of the fabrication process that can also affect 
cell viability include air flow rate, stirring rate of the CaCl2 solution, and extrusion force 
(push speed).  Effective evaluation of microencapsulated cell viability is highly important 
for better bioprocess control and quality assurance [4]. 
The viability of fibroblast cells encapsulated in alginate microcapsules, both 
uncoated and chitosan-coated, after the fabrication process is measured by a live-dead 
cell assay.  Live-dead cell assay is a simple method involving the staining of cells with 
staining solution consisting of an aqueous solution, calcein-AM, and ethidium 
homodimer-1.  Calcein-AM is a widely used green fluorescent cell marker that readily 
passes through the cell membrane and is retained in the cytoplasm of viable cells [11].  
The live cells produce a green fluorescence at an excited wavelength of 485 ± 10nm.  
Dead cells are labeled with ethidium homodimer-1, emitting red fluorescence at 530 ± 
12.5nm [4].  The results of the assay show that some cells are able to remain viable 
during the fabrication process of alginate microcapsules. 
The viability of the cells in the microcapsules over time is evaluated through the 
biochemical assay, resazurin also known as alamar blue.  Resazurin is a water-soluble 
extracellular redox indicator that can be reduced by living cells.  Resazurin assay has its 
advantages of being nontoxic to cells and being directly proportional to the number of 
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viable cells [4].  The way in which the resazurin assay works is that the oxidized form of 
the alamar blue enters the cytosol and is converted to the reduced form by viable cells.  
The number of viable cells is related to the amount of the reduced form of alamar blue by 
evaluating the absorbance [1].  As presented in Figure 3.12, the number of viable 
encapsulated fibroblast cells decreases over time.  More viable cells are detected in the 
uncoated alginate microcapsules compared to the fibroblast cells encapsulated in 
chitosan-coated alginate microcapsules.  A possible rationalization for this could be that 
the resazurin solution could not easily diffuse into the microcapsules due to the additional 
chitosan membrane.  Although this additional chitosan membrane provides stability for 
the microcapsules, it also reduces the size of the pores thus affecting the diffusion rate 
into and out of the spheres.  Another reason could be traced back to human error.  During 
the transfer and washing steps of the microcapsules and the aspiration of the solution in 
the wells each day, some of the microcapsules are lost during the process.  Cell damage 
during the fabrication process may potentially be another explanation for the decrease in 
cell viability. 
As a result from the two assays, a significant amount of the fibroblast cells 
remained viable initially as it is proved by the live-dead cell assay. However, they are 
unable to remain alive for a long period of time as it is shown by the results of the 
resazurin assay.  The explanation can be linked to the fact that the cells are remained in 
suspension in the microcapsule despite the diffusion of the necessary nutrients to 
maintain cell viability and growth.  It is necessary for cells to adhere to a surface in order 
to proliferate well. 
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Finally, the effect of the 3D microcapsule microenvironment on the proliferation 
and differentiation of mouse OCT4-GFP embryonic stem cells is studied.  OCT4-GFP is 
a transcription factor protein with a green fluorescent protein that expresses a green 
fluorescence in undifferentiated embryonic stem cells.  It is a frequently used marker for 
undifferentiated cells.  Image of the nonencapsulated mouse OCT4-GFP embryonic stem 
cell subculture expressing the OCT4 gene is presented in Figure 4.3.  The subculture is 
viewed under a fluorescence microscope at 10x magnification.  Image is taken with a 
Nikon digital camera connected to the microscope. 
Phase GFP Expression 
  
Figure 4.3  Mouse embryonic stem cells expressing the OCT4-GFP gene by green 
fluorescence indicate that the cells are in an undifferentiated state. 
 
After the encapsulation of mouse OCT4-GFP embryonic stem cells, the 
microcapsules are incubated in differentiation medium for two days with medium change 
occurring every day.  On each day of culture, microcapsules are observed by fluorescence 
microscopy to detect any GFP expression of the cells within the spheres.  After 2 days of 
culture, sodium citrate in sodium chloride is used to release the encapsulated mouse 
embryonic stem cells from the microcapsules.  Sodium and citrate are non-gelling ions 
and chealtors that can result in the dissolution of the alginate matrix.  The cells are then 
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fixed with paraformaldehyde and analyzed using flow cytometry.  Flow cytometry is 
used because the images by fluorescence microscopy alone are not sufficient enough to 
determine the success or failure of mouse embryonic stem cell differentiation.  The 
results from flow cytometry analysis reveal that mouse embryonic stem cells are able to 
differentiate when encapsulated in alginate microcapsules.  More differentiated stem cells 
are found with the uncoated microcapsules when compared to chitosan-coated 
microcapsules.  Therefore, the 3D stem cell microenvironment has the ability to control 
the proliferation and differentiation of encapsulated mouse OCT4-GFP embryonic stem 
cells through microcapsule membrane coating.  
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CHAPTER 5    
CONCLUSION 
 
The main focus of this work is to optimize alginate-based microcapsules using a co-axial 
air flow method and study how the microcapsule microenvironment affects the 
proliferation and differentiation of mouse OCT4-GFP embryonic stem cells.  The 
microcapsule parameters are first determined through a series of experiments that include 
the selection of microcapsule fabrication materials and optimization of microcapsule size.  
The microcapsules are then tested for mechanical stability and membrane permeability.  
Both of these characteristics are important for the application of these microcapsules in 
biomedical situations.  The viability of cells within the microcapsules is then examined 
because it is crucial that cells remain alive prior to their purpose under study.  Overall, 
the analysis from flow cytometry demonstrates that the microenvironment can control the 
proliferation and differentiation of mouse embryonic stem cells. 
Some improvements may be necessary in the alginate microcapsule scaffold 
presented in this study.  Future work can include finding ways to increase the cell 
viability within the microcapsules, coating the spheres with additional membranes to 
have a better control of the permeability, developing ways to produce uniform-shaped 
small spheres, and possibly try to differentiate the mouse embryonic stem cells to a 
specific lineage.  Methods for mammalian cell encapsulation are constantly being 
improved to achieve smaller size microcapsules, better mechanical stability, lower shear 
exerted on the cell suspension during sphere formation, versatility in the selection of 
biomaterials, and higher throughput.  
 52 
 
APPENDIX   
EFFECT OF ALGINATE CONCENTRATION ON MICROCAPSULE SIZE 
Figures A.1 and A.2 show the effect of alginate concentration on microcapsule size.  
Alginate concentrations of 1.5%, 2.0%, 2.5%, and 3.0% are tested.  Each alginate 
solution is extruded through a 30 gauge needle with an application of 15SCFH air flow 
rate at the needle tip into 0.15M CaCl2 solution under gentle stirring. 
Figure A.1  Increasing the alginate concentration results in larger size microcapsules.  
Alginate microcapsules are swelled and monitored for 4 days.
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